Pure Biologics Spólka Akcyjna (PUR.WA)
PLN 15.22
(-8.86%)
PLN 15.22
(-8.86%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 95 Thousand | 662 Thousand | 254 Thousand | 572 Thousand | 16.75 Million | 9.53 Million |
| Cost of Revenue | 2.66 Million | 6.06 Million | 4.28 Million | 273 Thousand | 3.95 Million | 2.84 Million |
| Gross Profit | -2.57 Million | -5.4 Million | -4.02 Million | 299 Thousand | 12.79 Million | 6.69 Million |
| Operating Expenses | 29.14 Million | 19.27 Million | 6.46 Million | 11.85 Million | 17.16 Million | 7.32 Million |
| Selling, General and Administrative Expenses | 6.53 Million | 8.02 Million | 3.79 Million | 6.01 Million | 4 Million | 2.11 Million |
| Research and Development Expenses | - | 23.78 Million | 20.58 Million | 18.38 Million | 14.92 Million | 4.6 Million |
| Other Expenses | 22.6 Million | 11.24 Million | 2.66 Million | -12.54 Million | 13.16 Million | 5.21 Million |
| Cost and Expenses | 31.81 Million | 25.34 Million | 10.74 Million | 12.12 Million | 21.11 Million | 10.16 Million |
| Operating Income | -31.71 Million | -24.62 Million | -10.48 Million | -11.55 Million | -4.36 Million | -631.01 Thousand |
| Interest Expense | 3.83 Million | 329 Thousand | 227 Thousand | 349 Thousand | 157.17 Thousand | 14.15 Thousand |
| Income Tax Expense | - | 769 Thousand | 1.3 Million | 349 Thousand | 157.17 Thousand | -44.16 Thousand |
| Earnings before Tax | -35.69 Million | -25.6 Million | -11.76 Million | -11.75 Million | -4.54 Million | -689.34 Thousand |
| Net Income | -35.69 Million | -26.37 Million | -13.07 Million | -12.1 Million | -4.7 Million | -689.34 Thousand |
| Earnings Per Share Basic | -11.19 | -11.87 | -5.88 | -7.32 | -3.09 | -0.59 |
| Earnings Per Share Diluted | -10.85 | -11.87 | -5.88 | -7.32 | -3.09 | -0.59 |
| Weighted Average Shares Outstanding | 3.18 Million | 2.22 Million | 2.22 Million | 1.65 Million | 1.52 Million | 1.17 Million |
| Weighted Average Shares Outstanding (Diluted) | 3.28 Million | 2.22 Million | 2.22 Million | 1.65 Million | 1.52 Million | 1.17 Million |
| Gross Margin | -27.09 | -8.17 | -15.85 | 0.52 | 0.76 | 0.70 |
| EBIT Margin | -274.49 | -33.24 | -29.68 | -14.51 | -0.22 | -0.05 |
| Profit Margin | -375.73 | -39.84 | -51.46 | -21.16 | -0.28 | -0.07 |
| EBITDA | -26.07 Million | -22.77 Million | -7.53 Million | -8.29 Million | -1.64 Million | -464.5 Thousand |
| Earnings Before Tax Margin | -333.87 | -37.20 | -41.27 | -20.20 | -0.26 | -0.07 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | -3000.00 | 3000.00 | 95 Thousand | 9000.00 | 56 Thousand | 1000.00 |
| Cost of Revenue | -13 Thousand | 265 Thousand | 2.66 Million | 386 Thousand | 641 Thousand | 693 Thousand |
| Gross Profit | 10 Thousand | -262 Thousand | -2.57 Million | -377 Thousand | -585 Thousand | -692 Thousand |
| Operating Expenses | -640 Thousand | 4.34 Million | 27.23 Million | 7.57 Million | 5.66 Million | 8.61 Million |
| Selling, General and Administrative Expenses | 848 Thousand | 2.77 Million | - | 2.15 Million | 1.06 Million | 925 Thousand |
| Research and Development Expenses | - | 1.56 Million | - | 7.85 Million | 7.04 Million | 11.15 Million |
| Other Expenses | -1.48 Million | 3.73 Million | - | - | - | - |
| Cost and Expenses | -653 Thousand | 4.6 Million | 29.9 Million | 7.95 Million | 6.3 Million | 9.3 Million |
| Operating Income | 486 Thousand | -4.6 Million | -31.71 Million | -9.85 Million | -6.25 Million | -9.3 Million |
| Interest Expense | 301 Thousand | 337 Thousand | 3.83 Million | 814 Thousand | 1.34 Million | 792 Thousand |
| Income Tax Expense | 4.2 Million | -7000.00 | 1.78 Million | -466 Thousand | 1000.00 | 179 Thousand |
| Earnings before Tax | 699 Thousand | -4.97 Million | -35.69 Million | -11.13 Million | -7.59 Million | -9.91 Million |
| Net Income | -2.99 Million | -4.97 Million | -35.69 Million | -11.13 Million | -7.59 Million | -9.91 Million |
| Earnings Per Share Basic | -0.90 | -1.49 | - | -3.49 | -2.36 | -3.08 |
| Earnings Per Share Diluted | -0.90 | -1.49 | - | -3.39 | -2.36 | -3.08 |
| Weighted Average Shares Outstanding | 3.32 Million | 3.32 Million | 3.18 Million | 3.18 Million | 3.21 Million | 3.21 Million |
| Weighted Average Shares Outstanding (Diluted) | 3.32 Million | 3.32 Million | 3.28 Million | 3.28 Million | 3.21 Million | 3.21 Million |
| Gross Margin | -3.33 | -87.33 | -27.09 | -41.89 | -10.45 | -692.00 |
| EBIT Margin | -296.33 | -1446.33 | - | -990.00 | -86.75 | -7613.00 |
| Profit Margin | 997.33 | -1656.67 | -375.73 | -1237.56 | -135.66 | -9915.00 |
| EBITDA | 889 Thousand | -4.33 Million | - | -8.91 Million | -4.85 Million | -7.61 Million |
| Earnings Before Tax Margin | -162.00 | -1534.67 | -333.87 | -1095.33 | -111.61 | -9302.00 |
JAGSNPHARM
G1A
JROOF
GGP
NXC
AKZOY